Diffuse Large B-cell lymphoma: Prognostic markers and their impact on therapy

被引：29
作者：
Jamil, Muhammad O. [1 ]
Mehta, Amitkumar [1 ]
机构：
[1] Univ Alabama Birmingham, Dept Med, Hematol & Oncol, 1720 2nd Ave South,NP2540N, Birmingham, AL 35294 USA
来源：
EXPERT REVIEW OF HEMATOLOGY | 2016年 / 9卷 / 05期
关键词：
Diffuse large B cell lymphoma; Prognostic marker; lenalidomide; ibrutinib; brentuximab vedotin; bortezomib; POSITRON-EMISSION-TOMOGRAPHY; CHOP-LIKE CHEMOTHERAPY; R-CHOP; MYC REARRANGEMENTS; MOLECULAR SUBTYPES; BURKITT-LYMPHOMA; ELDERLY-PATIENTS; POOR-PROGNOSIS; YOUNG-PATIENTS; OPEN-LABEL;
D O I：
10.1586/17474086.2016.1146584
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Diffuse large B-cell lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma (NHL). DLBCL is clinically, pathologically and molecularly heterogeneous disease. Various clinical, pathological and molecular markers have been developed to characterize the disease. Based on these characterizations, new targeted agents are being investigated to optimize the treatment and improve the outcomes of DLBCL. Enhanced molecular understanding, invention of targeted agents and immunotherapy has opened the doors for improvement in the treatment of DLBCL. In this review, we will discuss various prognostic markers of DLBCL and their potential therapeutic implications.
引用
收藏
页码：471 / 477
页数：7
相关论文
共 77 条
  • [1] MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
    Alencar, Alvaro J.
    Malumbres, Raquel
    Kozloski, Goldi A.
    Advani, Ranjana
    Talreja, Neha
    Chinichian, Shideh
    Briones, Javier
    Natkunam, Yasodha
    Sehn, Laurie H.
    Gascoyne, Randy D.
    Tibshirani, Rob
    Lossos, Izidore S.
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (12) : 4125 - 4135
  • [2] Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    Alizadeh, AA
    Eisen, MB
    Davis, RE
    Ma, C
    Lossos, IS
    Rosenwald, A
    Boldrick, JG
    Sabet, H
    Tran, T
    Yu, X
    Powell, JI
    Yang, LM
    Marti, GE
    Moore, T
    Hudson, J
    Lu, LS
    Lewis, DB
    Tibshirani, R
    Sherlock, G
    Chan, WC
    Greiner, TC
    Weisenburger, DD
    Armitage, JO
    Warnke, R
    Levy, R
    Wilson, W
    Grever, MR
    Byrd, JC
    Botstein, D
    Brown, PO
    Staudt, LM
    [J]. NATURE, 2000, 403 (6769) : 503 - 511
  • [3] [Anonymous], 2014, CLIN ADV HEMATOL ONC, V12, P18
  • [4] Thalidomide analogues as anticancer drugs
    Aragon-Ching, Jeanny B.
    Li, Haiqing
    Gardner, Erin R.
    Figg, William D.
    [J]. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, 2007, 2 (02) : 167 - 174
  • [5] Double-hit B-cell lymphomas
    Aukema, Sietse M.
    Siebert, Reiner
    Schuuring, Ed
    van Imhoff, Gustaaf W.
    Kluin-Nelemans, Hanneke C.
    Boerma, Evert-Jan
    Kluin, Philip M.
    [J]. BLOOD, 2011, 117 (08) : 2319 - 2331
  • [6] Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
    Barrans, Sharon
    Crouch, Simon
    Smith, Alex
    Turner, Kathryn
    Owen, Roger
    Patmore, Russell
    Roman, Eve
    Jack, Andrew
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3360 - 3365
  • [7] CD30: seeing is not always believing
    Blum, Kristie A.
    [J]. BLOOD, 2015, 125 (09) : 1358 - 1359
  • [8] Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma
    Broyde, Adi
    Boycov, Olga
    Strenov, Yulia
    Okon, Elimelech
    Shpilberg, Ofer
    Bairey, Osnat
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2009, 84 (06) : 338 - 343
  • [9] HIV-associated lymphomas and gamma-herpesviruses
    Carbone, Antonino
    Cesarman, Ethel
    Spina, Michele
    Gloghini, Annunziata
    Schulz, Thomas F.
    [J]. BLOOD, 2009, 113 (06) : 1213 - 1224
  • [10] Chan WC, 1997, BLOOD, V89, P3909
12345678